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Role of the type 1 angiotensin receptor AT1 in
immune-mediated glomerular injury
The renin-angiotensin system (RAS) plays an important
role in the pathogenesis of glomerular diseases. To delin-
eate more precisely the role of RAS in creating renal in-
jury, knockout mouse strains lacking the angiotensin type 1
or type 2 receptors (AT1 and AT2) have proven very
informative.
Hence, in their elegant study that was published in the
April 2009 issue of the Journal of Clinical Investiga-
tion, Crowley et al. have tested the effect of a targeted
disruption of the AT1 receptor on the glomerular dis-
ease process in a mouse lupus nephritis model [1]. MRL-
Faslpr/lpr mice develop a severe lupus-like autoimmune syn-
drome that is characterized by severe proliferative immune-
complex glomerulonephritis, autoantibody production and
arthritis, in addition to a peculiar lymphoproliferative
phenotype.
In their study, a unique MRL-Faslpr/lpr mouse strain that
lacks themajor type 1 angiotensin receptor (AT1A) was gen-
erated to examine the role of angiotensin in the pathogene-
sis of autoimmune glomerular injury. Despite the absence
of hypertension, AT1A deficiency did not protect against
disease but worsened kidney pathology and proteinuria,
and accelerated mortality in these mice. Transplantation of
AT1A-deficient bonemarrow intoMRL-Faslpr/lpr did not af-
fect survival, suggesting that the enhanced disease severity
was not a consequence of immune cell alteration. Further-
more, AT1A-deficient MRL-Faslpr/lpr mice did not display
increased extrarenal tissue injury, and the lymphoprolifer-
ative phenotype as well as the circulating antinuclear anti-
bodies were not changed.
How could this worsened disease in AT1A-deficient
MRL-Faslpr/lpr mice be explained? Unlike humans, rodents
are known to express a second type 1 angiotensin recep-
tor (termed AT1B), in particular in glomerular podocytes.
Mice with AT1A deficiency display a higher renin produc-
tion and an enhanced activity of RAS. Evidence is then
provided in this study for exaggerated AT1B receptor acti-
vation in podocytes, manifesting as podocyte injury and in-
creased production of inflammatory mediators. Treatment
with the angiotensin receptor blocker (ARB) losartan that
blocks both type 1 angiotensin receptors indeed reduced
glomerular injury. Thus, it appears that the glomerular
type 1 angiotensin receptor AT1B mediated the augmented
kidney injury and inflammation in AT1A-deficient MRL-
Faslpr/lpr mice. Alltogether, the data suggest that an activa-
tion of AT1 receptors may be sufficient to augment autoim-
mune glomerular injury and inflammation in the absence of
hypertension.
SLE, hypertension and the RAS
In addition to the more direct effects of angiotensin II on
the cardiovascular system, the RAS promotes immune and
inflammatory tissue injury (Figure 1). Thus, it has been
shown for example that activation of the type 1 angiotensin
receptor AT1 augments alloreactivity in experimental allo-
graft transplantation [2]. Most of the actions of angiotensin
II to enhance inflammation and tissue injury appear to be
mediated by the AT1 receptor. Activation of the oppos-
ing angiotensin receptor AT2 is generally felt to mediate
protection from inflammation [3]; however, in other situa-
tions, activation of AT2 has also been linked to inflamma-
tion, such as increased chemokine expression in the kidney
[4].
It is well known that the extent of hypertension has a
major impact on target organ damage in human SLE [5].
Association studies in patients with lupus nephritis have
linked high blood pressure to accelerated progression of
renal failure. Case series have shown a general benefit of
RAS inhibition in patients with SLE [6], but so far no
controlled trials with ACEi or ARB have been performed.
Although there are no such randomized trials in humans
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Fig. 1. Pathophysiological alterations that are mediated by the different
AT receptors. In humans, there is an AT1 and an AT2 receptor that have
antagonizing functions. In rodents, there is an alternative AT1 receptor
termed AT1B that is expressed in glomeruli by podocytes, and which is
felt to have similar functions as the AT1A receptor.
with SLE, it is felt that RAS inhibition confers protection
in human lupus nephritis.
Animal models that apply pharmacological blockade of
the RAS or targeted deletion of the angiotensin receptor
genes have proved quite useful to gain a better understand-
ing of how RAS promotes immune/inflammatory renal in-
jury. Studies in lupus mice have revealed that inhibition of
RAS with ACEi or ARB is beneficial, reducing glomerular
injury and albuminuria, and TGF-β production, the lat-
ter being a major mediator of fibrosis [7,8]. However, the
role of RAS in regulating immune responses is complex,
and further experimental studies are needed to elucidate
themechanisms of angiotensin-mediated autoimmune renal
injury.
Previous studies have shown that AT1A receptor knock-
out mice display marked stimulation of renin expression,
increased circulating levels of angiotensin II, butwith rather
low-normal blood pressure. This marked activation of RAS
would predict exaggerated stimulation of the residual ele-
ments of the system, including activation of other recep-
tors of RAS. In the study by Crowley et al., it was antic-
ipated that elimination of the major angiotensin receptor
AT1A would be protective on murine lupus nephritis. Yet
it was found that the autoimmune nephritis was acceler-
ated. In mice, but not in humans, there is a second AT1
receptor—AT1B—whose expression was preserved in this
model. As in the murine kidney, the AT1B receptor is exclu-
sively expressed by glomerular podocytes, and the AT1A-
deficient MRL-Faslpr/lpr mouse strain provides a fortuitous
model wherein the renal AT1 receptor expression is limited
to the glomerulus. Thus, it could be concluded that the sys-
temic activation of RAS in this lupus mouse line promoted
more severe injury by stimulating the residual glomerular
AT1B receptors.
Role of RAS inhibition in immune/inflammatory
renal injury
From this experimental study, one would like to extrapolate
that the blockade of RAS with ACEi or ARB is very useful
to protect the kidney in autoimmune injury such as in pa-
tients with lupus nephritis, or in patients with other immune
complex-mediated glomerulonephritides. This has in fact
been shown in previous experimental studies, and is shown
again here by the fact that the ARB losartan prevented the
enhanced disease process in lupus mice with AT1A defi-
ciency [1,8]. One does not need to mention the numerous
studies that have documented the beneficial effects of ACEi
or ARB in various glomerular diseases, including immune-
mediated entities such as IgA nephritis or membranous
GN, or non-immune glomerular diseases such as diabetic
nephropathy.
What needs to be stated is the fact that the mecha-
nisms by which RAS promotes immune or inflammatory
glomerular damage may be far more complex than pre-
viously thought, and may not be operating solely through
the AT1 receptors. Various components of RAS, includ-
ing prorenin, renin, angiotensin1–7 to name a few, and the
non-AT1 receptors AT2, Ang1–7 receptor (Mas) and others
may target the immune system and renal parenchymal cells
within the glomerulus in a sophisticated way, not to men-
tion the complex interplay with other systems that include
the kallikrein–bradykinin system, the NO system and the
prostaglandins and thromboxanes. A dysbalance in these
systems may cause different patterns of glomerular injury.
Thus, one could speculate that in the future there might
be more refined therapeutic strategies to influence these
interacting systems. Despite decades of intense research,
RAS is still always good for a surprise, and the study by
Crowley et al. provides another elegant example of this ever
increasingly complex system.
In conclusion, activated RAS has a direct negative impact
on glomerular injury processes, occurring independently of
its effect on blood pressure. Currently, the pharmacological
blockade of RAS with ACEi or ARB, and perhaps direct
renin inhibitors, appears to be the best available strategy to
improve the negative impact of RAS activation on glomeru-
lar injury and loss of renal function.
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